APIM Therapeutics's CSO and NTNU Professor Marit Otterlei presents latest results obtained with ATX-101 in preclinical efficacy models in the 14th International Congress on Targeted Anticancer Therapies, 21-23 March, 2016, Washington, USA. A copy of the poster presented is available here.
